🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

842 results for “Eli” Clear

  1. ASPAVELI 1 080 mg solution for infusion

    Pharma Mar S.A.

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 2 small molecule active

    1 trial

  2. ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Pharma Mar S.A.

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule active

    1 trial

  3. Abemaciclib, Abemaciclib, Verzenios 50 mg film-coated tablets, TEMOZOLOMIDE

    Eli Lilly Co.

    Glioma

    phase 2 small molecule active

    1 trial

  4. Abemaciclib, TEMOZOLOMIDE , Verzenios 50 mg film-coated tablets, IRINOTECAN

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  5. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  6. Adebrelimab

    China SXT Pharmaceuticals

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  7. Adebrelimab (PD-L1 inhibitor)

    China SXT Pharmaceuticals

    Pancreatic Cancer Metastatic

    phase 2 small molecule active

    1 trial

  8. Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

    First Tracks Biotherapeutics

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  9. Adebrelimab+Albumin paclitaxel +Cisplatin

    First Tracks Biotherapeutics

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  10. Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

    First Tracks Biotherapeutics

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

  11. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  12. Alpelisib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  13. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi Pharma Bristol-Myers Squibb

    Hidradenitis

    phase 2 small molecule active

    1 trial

  14. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi Pharma Bristol-Myers Squibb

    Coeliac disease

    phase 2 small molecule active

    1 trial

  15. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi Pharma Bristol-Myers Squibb

    Alopecia areata

    phase 2 small molecule active

    1 trial

  16. Amlitelimab, Placebo

    Sanofi Pharma Bristol-Myers Squibb

    Asthma

    phase 2 small molecule active

    1 trial

  17. Anrotinib plus Tirelizumab

    China SXT Pharmaceuticals

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  18. Apatinib+ SHR-1210（Camrelizumab）

    First Tracks Biotherapeutics

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  19. Atezolizumab

    Oncotelic Therapeutics

    Metastatic Lung Non-Small Cell Carcinoma

    phase 2 mab terminated

    1 trial

  20. Avastin 25 mg/ml concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, Cotellic 20 mg film-coated tablets, Ipatasertib, Cotellic, Cotellic, INAVOLISIB, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, Verzenios 50 mg film-coated tablets, Cotellic, Lynparza 100 mg film-coated tablets, Kadcyla 160 mg powder for concentrate for solution for infusion., LETRO-cell® 2,5 mg Filmtabletten, INAVOLISIB, Verzenios 100 mg film-coated tablets, INAVOLISIB, Lynparza 150 mg film-coated tablets

    Roche Registration Limited

    Persistent or Recurrent Rare Epithelial Ovarian Tumors

    phase 2 small molecule active

    1 trial

  21. Avelumab

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  22. Azeliragon

    vTv Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  23. BAY 1841788, DEGARELIX , LEUPRORELIN , TRIPTORELIN , GOSERELIN , TRIPTORELIN PAMOATE

    Cancer Prevention Pharma (Ireland) Limited

    Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  24. BEVACIZUMAB, IRINOTECAN, FOLINIC ACID, Telisotuzumab adizutecan, FLUOROURACIL

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources